SARS-CoV-2 vaccines in development

  title={SARS-CoV-2 vaccines in development},
  author={Florian Krammer},
  • F. Krammer
  • Published 23 September 2020
  • Biology
  • Nature
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed. Here I review the development of vaccines against SARS-CoV-2. Development was initiated when the genetic sequence of the virus became available in early January 2020, and has moved at an unprecedented speed… 

An overview of current COVID-19 vaccine platforms

COVID-19 Vaccines: A Primer for Clinicians.

A summary of the host immune responses to SARS-CoV-2 infection, the vaccine platforms being used with COVID-19 vaccine candidates undergoing, or about to undergo, Phase III clinical trial testing, and an overview of the key criteria necessary for COVID -19 vaccine efficacy and safety are provided.

Correlates of Vaccine-Induced Protection against SARS-CoV-2

Reports are reported on immunogenicity against natural SARS-CoV-2 infection, vaccine-induced immune responses and immunological markers that can be linked to protection and a comprehensive overview of possible efficacy measures and CoP.

Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward

This review analyzes the complexities, challenges, and other vital issues associated with the development of the SARS-CoV-2 vaccine to find the ways to speed up vaccine development.

mRNA Vaccines in the COVID-19 Pandemic and Beyond.

This review gives a detailed overview about the types of mRNA vaccines developed for SARS-CoV-2, discusses and compares preclinical and clinical data, gives a mechanistic overview about immune responses generated by mRNA vaccination, and speculates on the challenges and promising future of this emergent vaccine platform.

Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.

The primary efficacy endpoint for a random placebo-controlled clinical trial of a COVID-19 vaccine to be approved by US FDA should confer at least 50% protection against CO VID-19.

Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2.

An overview of therapeutic options for COVID-19 as well as vaccines for protection against SARS-CoV-2 is provided.

An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages

Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination

This review summarizes the main knowledge that is known about the humoral immune response during COVID-19 disease or after vaccination and should help to optimize vaccination strategies and public health decisions.

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants

The different types of vaccines designed and developed against SARS-CoV-2 are reviewed, placing emphasis on whether they are based on the complete S glycoprotein, its antigenic domains such as the receptor-binding domain (RBD) or short epitopes within the S Glycoprotein.



Development of an inactivated vaccine candidate for SARS-CoV-2

Preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies, support the clinical development and testing of Pi coVacc for use in humans.

A Scalable Topical Vectored Vaccine Candidate against SARS-CoV-2

The presented respiratory vaccine candidate is highly attenuated in primates per se, safe and lacking pre-existing immunity in human, and carries the potential for accelerated vaccine development against CoVID-19 for clinical studies.

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

A mouse model in which a SARS-CoV-2 strain was infectious and could cause an inflammatory response and moderate pneumonia is developed, and a panel of adaptive mutations potentially associated with the increased virulence are revealed.

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine.

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Analysis of the vaccine candidates in rhesus macaques showed that animals developed protective humoral and cellular immune responses when challenged with the SARS-CoV-2 virus, suggesting an immune correlate of protection.

SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness

A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development

Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection

The susceptibility of a few laboratory rodents to SARS-CoV-2 is evaluated at the Maximum Containment Laboratory, Indian Council of Medical Research National Institute of Virology, Pune, India.

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

It is shown that the adenovirus-vector-based vaccine ChAdOx1 nCoV-19, which encodes the spike protein of SARS- CoV-2, is immunogenic in mice and elicites a robust humoral and cell-mediated response.

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

A diverse collection of potent neutralizing antibodies against the SARS-CoV-2 spike protein have been isolated from five patients with severe COVID-19 and high serum neutralization titres, suggesting both of these regions at the top of the viral spike are immunogenic.

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2

It is shown that SARS-CoV-2 causes a respiratory disease in rhesus macaques that lasts between 8 and 16 days, which recapitulates the moderate disease that has been observed in the majority of human cases of COVID-19.